SEC Form 4 · accession 0000885590-15-000029

Bausch Health Companies Inc. · BHC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Financial Officer

Period of report

Apr 27, 2015

Accepted (ET)

Apr 28, 2015 · 4:38 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000885590

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock, no par value^F2,F1	Apr 27, 2015	M	22,500	—	A	306,007	D
Common Stock, no par value^F3	Apr 27, 2015	F	11,779	$0.00	D	294,228	D
Common Stock, no par value^F4	Apr 27, 2015	F	4,859	$0.00	D	289,369	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Share Units^F2,F1	—	Apr 27, 2015	M	22,500	D	—	—	Common Stock	22,500	0	D

F1Each performance-based Restricted Share Unit ("PSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
F2These RSUs were initially eligible to vest based on total shareholder return ("TSR") between a price of $42.70 starting on December 1, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 1, 2014, 50% on December 1, 2014 and 25% on March 1, 2015, contingent on TSR performance between 15% and 45% into between one and three Common Shares of common stock, respectively, with early vesting possible at higher TSR levels. These PSUs have now vested in full.
F3This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs.
F4This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Matching Restricted Share Units.